ijms-logo

Journal Browser

Journal Browser

Evidence-Based Principles of Diagnosis and Management of Hypertension in Modern Era

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 922

Special Issue Editor


E-Mail Website
Guest Editor
UNM Health Sciences Center, Albuquerque, NM, USA
Interests: kindney; internal medicine; nephrology; dialysis; acute kidney injury; hypertension; renal tubular acidosis; hemodialysis; clinical nephrology; regulation of gene expression; renal physiology; cirrhosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the continuation of our previous Special Issue entitled Advances in the Pathogenesis and Treatment of Hypertension.

The prevalence of hypertension has escalated significantly in adults aged 30–79 years rising from 650 million to 1.28 billion over the last three decades, based on recent publications. This is especially alarming due to the “silent” nature of hypertension. Hypertension is a leading cause of premature morbidity and mortality due to stroke, cardiovascular ailment and kidney failure.  If untreated, hypertension not only predisposes to stroke, but also exacerbates the outcome after ischemic or hemorrhagic stroke. In addition, hypertension can precipitate congestive heart failure. Further, hypertension can cause kidney damage and lead to kidney failure.

Major environmental risk factors for the development of hypertension include increased sodium intake, obesity, oxidative stress, physical inactivity, alcohol consumption, sleep apnea and an unhealthy diet. In addition, a number of genetic factors critical to the development of hypertension has been identified. How these genetic and environmental risk factors interact and contribute to the development of hypertension has been the subject of intensive investigation.

This issue of the International Journal of Molecular Science is bringing leading investigators in the field of hypertension and nephrology together along with the latest reviews on advances in the understanding of the role of the genetic and environmental factors responsible for the pathogenesis and treatment of hypertension.

Prof. Dr. Manoocher Soleimani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • primary hypertension
  • secondary hypertension
  • gestational hypertension
  • renin angiotensin aldosterone system
  • metabolic syndrome
  • salt overload

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

12 pages, 553 KiB  
Review
Onco-Hypertension: A Continuously Developing Field between Cancer and Hypertension
by Stefan Totolici, Ana-Maria Vrabie, Elisabeta Badila and Emma Weiss
Int. J. Mol. Sci. 2024, 25(6), 3442; https://doi.org/10.3390/ijms25063442 - 19 Mar 2024
Viewed by 653
Abstract
The prognosis of cancer patients has greatly improved in the last years, owing to the development of novel chemotherapeutic agents. However, this progress comes with an increasing occurrence of cardiovascular adverse reactions. A serious side effect is arterial hypertension (HT), which is the [...] Read more.
The prognosis of cancer patients has greatly improved in the last years, owing to the development of novel chemotherapeutic agents. However, this progress comes with an increasing occurrence of cardiovascular adverse reactions. A serious side effect is arterial hypertension (HT), which is the most frequent comorbidity encountered in cancer patients, influencing the outcomes in cancer survivors. Even though secondary HT related to specific chemotherapeutic agents, such as vascular endothelial growth factor inhibitors, is usually mild and reversible, in rare instances it can be severe, leading to discontinuation of chemotherapy. In addition, HT per se has been studied as a potential risk factor for cancer development. The relationship is even more complex than previously thought, as concerning evidence recently highlighted the potential oncogenic effects of antihypertensive drugs, particularly thiazide diuretics, which may increase the risk of skin cancer. As a result, in light of the similar risk factors and overlapping pathophysiological mechanisms between HT and cancer, a promising concept of onco-hypertension has emerged, aiming to improve the understanding of the complicated interplay between these two pathologies and maintain a balance between the efficacy and risks of both antihypertensive drugs and chemotherapy agents. Full article
Show Figures

Figure 1

Back to TopTop